QuidelOrtho Cash Flow Statement
QDEL / Health Care|5 years of annual SEC 10-K data (FY2020-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 5 fiscal years. All figures from audited SEC 10-K filings.
At a glance
Operating Cash Flow
$105M
FY2025
Free Cash Flow
-$83M
FY2025
Capital Expenditures
$188M
Cash used for long-term assets
Dividends Paid
N/A
FY2025
QuidelOrtho generated $105M in operating cash flow and negative free cash flow of $83M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score NaN (distress zone, below 1.23 threshold)
- Currently unprofitable: Net income is negative
- Cash-backed earnings: Operating cash flow exceeds net income
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2020 |
|---|---|---|---|---|---|
| Net Income | -$1.1B | -$2.1B | -$10.1M | $548.7M | $810.3M |
| Depreciation & Amortization | $442.0M | $453.4M | $457.2M | $283.6M | $48.8M |
| Operating Cash Flow | $105.2M | $83.0M | $280.2M | $885.3M | $629.7M |
| Capital Expenditures | $188.2M | $195.1M | $209.3M | $140.9M | $64.9M |
| Free Cash Flow | -$83.0M | -$112.1M | $70.9M | $744.4M | $564.8M |
| Share Buybacks | $0 | $0 | $7.2M | $74.3M | $43.7M |
| FCF Margin | -3.0% | -4.0% | 2.4% | 22.8% | 34.0% |